We are international
• about myeloma TEXT SIZE   
Recognizing and Addressing the Side Effects of Treatment


Osteonecrosis of the jaw is a condition whereby there is loss or destruction of the bone underneath the teeth. This loss of bone appears to be caused by a combination of poor blood supply and impaired bone remodeling or healing.

Osteonecrosis of the Jaw
    next      view all

Salvatore L. Ruggiero, DMD, MD Talks About Osteonecrosis of the Jaw (ONJ)

AAOMS Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws
Bisphosphonate-related osteonecrosis of the jaw (BRON) adversely affects the quality of life and produces significant morbidity in afflicted patients. Oral and maxillofacial surgeons have been responsible for counseling, managing, and treating a majority of these patients. The strategies set forth in this position paper were developed by a Task Force appointed by the American Association of Oral and Maxillofacial Surgeons (AAOMS).

American Society for Bone and Mineral Research (ASBMR) Issues report on ONJ risk
The American Society for Bone and Mineral Research (ASBMR) announced today the publication of a report that examines the link between a class of widely prescribed drugs used to strengthen bones and the disorder known as Osteonecrosis of the Jaw (ONJ). The report, authored by an international, multidisciplinary task force, was convened by the ASBMR to look at the possible association between ONJ, a deterioration of the jawbone, and a class of drugs known as bisphosphonates, which in recent years have been linked to the condition.

Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone.
An article from Cancer, in which researchers from the College of Dental Medicine, Nova Southeastern University in Fort Lauderdale, Florida present results of a study of 17 patients with cancer with bone metastases and 1 patient with osteopenia who received treatment with bisphosphonates and who subsequently developed osteonecrosis of the mandible and/or maxilla.

FDA Oncologic Drugs Advisory Committee Meeting On Aredia And Zometa
The committee discussed safety concerns, specifically osteonecrosis of the jaw (ONJ), associated with two bisphosphonates, NDA 21-223, ZOMETA® (zoledronic acid) Injection and AREDIA®, NDA 20-036 (pamidronate disodium for injection), both from Novartis Pharmaceuticals Corp.

Journal of the National Cancer Institute
Intravenous Bisphosphonate Therapy andInflammatory Conditions or Surgery of the Jaw: A Population-Based Analysis

Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma
A multidisciplinary panel consisting of hematologists, dental specialists, and nurses specializing in the treatment of myeloma reviewed available data concerning the use of bisphosphonates. Guidelines for the use of bisphosphonates in MM were developed. This link is to the full article.

NEJM Publishes Correspondence On ONJ
The New England Journal of Medicine published correspondence from Drs. Durie, Richardson, Duck and Tarassoff on Osteonecrosis of the Jaw in its July 7, 2005 issue (N Engl J Med. 2005 Jul 7;353(1):99-102; discussion 99-102.)

Time Dependent Correlation with AREDIA and ZOMETA Use
At the 2004 Annual Meeting of the American Society of Hematology, Dr. Durie presented the results of the web-based survey that many of you were kind enough to help us with. We are encouraged by the discussions that have ensued and are hopeful that this will help us raise awareness about this very serious issue and facilitate timely action.

Osteonecrosis Web Survey Results Presented At 2004 ASH Meeting

    next      view all